FNLCR, BOP
SOP Number: 24404
Effective Date: NOV 26 2019
Title: Content of an lnvestigational New Drug Application (IND)
UNCONTROLLED COPY FOR TRAINING AND REFERENCE PURPOSES ONLY
โข The Institutional Review Board (IRS) approved informed consent form and IRB
approval letter, if available. If not available, the form and letter should be
submitted in an amendment to the IND when they become available;
โข Information specific to each investigator using Form FDA 1572. A current FDA
Form-1572 can be obtained using the following website:
http://www.fda.gov/media/71816/download.
5.9
Chemistry, Manufacturing, and Control (CMC) Information [21 CFR 312.23(a)(7)]: This
section describes the composition, manufacture, and control of the drug substance and the
drug product to assure the identification, quality, purity, and strength of the investigational
drug. This information is provided in Module 3 of an IND. A detailed description of the
content of the Chemistry, Manufacturing, and Control information for the drug substance
and the drug product are described separately in
SOP 24411
-
Preparation of a
Chemistry, Manufacturing, and Controls Section in Common Technical Document
(CTD) Format.
The amount of supporting CMC information varies with the investigational phase, the scope
of, the duration of, and the dosage form used for the clinical trial.
5.9.1
The information contained in the CMC section for both the bulk drug substance and
the final drug product should include: description/composition information, name
and address of the manufacturer, method of manufacture (including
container/c losure inform ation), ana lytical test and specifications(including assay
descriptions) to assure the identity, strength, quality, and purity of the drug
substance and product, and stability data demonstrating the drug product will be
stable throughout the toxicology studies and course of the clinical trial.
5.9.2
For Gene Therapy product IND's, the information reques ted in the FDA's March 6,
2000, Gene Therapy Letter should be provided as part of the CMC or can be
included by reference using a letter of authorization issued by the manufacturer to
cross reference their Drug Master File.
5.9.3
The FDA provides guidance for the content of CMC information for Phase 1 studies
of drugs in the guidance document entitled Content and Format of lnvestigational
New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Wei/-
Characterized, Therapeutic, Biotechnology-derived Products, November 1995; and
Phase 2 and 3 studies of drugs in the guidance document entitled INDs for Phase 2
and 3 Studies of Drugs-Chemistry, Manufacturing, and Controls Information, May
2003.
5.10
Pharmacology and Toxicology Information [21 CFR 312.23(a)(8)]: Discussion of
pharmacological and toxicological studies conducted in animals or in vitro used by the
sponsor to support the safety and possibly the efficacy of the proposed investigational
study. The extent of the pharmacological and toxicological study requirements varies with
the phase of the clinical study. As drug development proceeds, the sponsor submits
updated pharmacology and toxicology information in an amendment. Additional
pharmacology and toxicology guidance can be found in the guidance document entitled
Content and Format of lnvestigational New Drug Applications (INOs) for Phase 1 Studies of
Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products,
This procedure is made available through federal funds from the National Cancer Institute, NIH, under contract